Evidence map›Paper›PMID 37656260›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2024

Estimating surgery, radiotherapy and systemic anti-cancer therapy treatment costs for cancer patients by stage at diagnosis.

Lorna Wills, Diana Nagarwalla, Clare Pearson, Sean McPhail, Rose Hinchliffe, Ben Sharpless, Fahmina Fardus-Reid, Lyndsy Ambler, Samantha Harrison, Jon Shelton

Abstract read
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lorna WillsCancer Research UK, 2 Redman Place, London, E20 1JQ, UK.
Diana NagarwallaCancer Research UK, 2 Redman Place, London, E20 1JQ, UK. Diana.Nagarwalla@cancer.org.uk.ORCID http://orcid.org/0000-0001-8716-5446
Clare PearsonCancer Research UK, 2 Redman Place, London, E20 1JQ, UK.
Sean McPhailNational Cancer Registration and Analysis Service, NHS Digital, 10 South Colonnade, London, E14 4PU, UK.
Rose HinchliffeCancer Research UK, 2 Redman Place, London, E20 1JQ, UK.
Ben SharplessCancer Research UK, 2 Redman Place, London, E20 1JQ, UK.
Fahmina Fardus-ReidCancer Research UK, 2 Redman Place, London, E20 1JQ, UK.
Lyndsy AmblerCancer Research UK, 2 Redman Place, London, E20 1JQ, UK.
Samantha HarrisonCancer Research UK, 2 Redman Place, London, E20 1JQ, UK.
Jon SheltonCancer Research UK, 2 Redman Place, London, E20 1JQ, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe increasing burden of cancer has economic implications for the healthcare system in England. However, there is limited evidence on the cost of cancer treatment. We calculated the costs of initial cancer treatment (resection, radiotherapy, systemic anti-cancer therapy [SACT]) based on stage at diagnosis.

methodsData from England's National Cancer Registration Dataset were matched to English Hospital, Radiotherapy and SACT data for breast, lung, prostate, colon and rectal cancers diagnosed between 2016 and 2018. Treatment data were matched to National Schedule of Reference Costs data to calculate the cost of each treatment event.

resultsBreast, colon and rectal cancers treated with resection, radiotherapy or SACT had increasing costs with later stage at diagnosis; costs for lung and prostate cancers were lower at stages 1 and 4 compared to stages 2 and 3. In general, surgery and SACT were the most expensive treatments. Radiotherapy and SACT costs showed little change across stages 1-3; radiotherapy costs decreased in stage 4, while SACT costs increased.

conclusionsThis analysis estimates initial treatment costs by stage based on observed data. Future research can build on this to provide more comprehensive costings associated with cancer; this is important for future planning of cancer services.

Indexed as

NeoplasmsNeoplasm StagingAgedAntineoplastic AgentsEnglandFemaleHealth Care CostsHumansMaleMiddle AgedRadiotherapyAntineoplastic AgentsCancerCostsStage at diagnosisTreatment

Identifiers

PMID37656260
PMCPMC11192664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.